Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GLS | O94925 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506904 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL19214733 | 0.83 | ALDH1A1 (0.52) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL13299192 | 0.81 | ALDH1A1 (0.53) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL12788682 | 0.79 | GLS (0.60) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL18733004 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL17489160 | 0.77 | GLS (0.75) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL16447617 | 0.77 | ALDH1A1 (0.64) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL22927481 | 0.76 | ALDH1A1 (0.39) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL23194585 | 0.75 | ALDH1A1 (0.52) | ALDH1A1KDM4EGLAGLSLMNA | |
| SCHEMBL2020938 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-08-25 | — | — | US | disclosed |
| US-8962637-B2 | Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors | DEBIOPHARM S.A. (CH) | 2015-02-24 | — | — | US | disclosed |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | DEBIOPHARM S.A. (CH) | 2013-06-06 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-8440679-B2 | Bicyclic compounds and their uses as dual c-SRC / JAK inhibitors | DEBIOPHARM S.A. (CH) | 2013-05-14 | — | — | US | disclosed |
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LTD. (IN) | 2013-01-10 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012518-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | ALDH1A1 3455/4885KDM4E 1224/4885GLA 4716/4885 |
| US-20160244435-A1 | EXPANDED THERAPEUTIC POTENTIAL IN NITROHETEROARYL ANTIMICROBIALS | NQO1, TXN2, MPO | ALDH1A1 1589/4885KDM4E 3910/4885GLA 3055/4885 |
| US-20130143895-A1 | BICYCLIC COMPOUNDS AND THEIR USES AS DUAL C-SRC / JAK INHIBITORS | JAK2, SRC, JAK1 | ALDH1A1 3455/4885KDM4E 1224/4885GLA 4716/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | ALDH1A1 1604/4885KDM4E 1058/4885GLA 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.